Provider offer
CoreAge Rx — Time Out product page ↗
Formula, advertised starting price, consultation steps, and product cautions. Commercial claims are not independent outcome evidence.
THE SOURCE NOTES
Open the
original record.
Provider pages describe offers. Studies address specific questions. Regulatory and dermatology sources add a different kind of context. Last checked September 24, 2026.
Provider offer
Alloy — M4 Face Cream Rx ↗
Advertised $150 three-month supply and prescription pathway. Marketing percentages need the underlying study context.
Provider-hosted study report
Alloy M4 clinical study report, June 2024 ↗
A 12-week, single-site, randomized, double-blind, vehicle-controlled study of 90 women across three groups. Not a head-to-head trial of current retail brands.
Provider offer
Musely — The Aging Repair Cream ↗
Advertised monthly equivalent with a two-month supply, prescription access, and explicitly self-reported patient outcome claims.
Provider offer
Midi Health — Estriol+ Face Cream ↗
Advertised $149 for a 90-day supply (90 mL). Exact dispensed formulation and eligibility require confirmation.
Provider process
Midi — Custom Rx Express ↗
Public intake, clinician decision, and ordering process; advertised timing is not a service guarantee.
Regulatory guidance
FDA — Understanding the risks of compounded drugs ↗
Compounded drugs are not FDA-approved; FDA does not review them for safety, effectiveness, or quality before marketing.
Regulatory guidance
FDA — Menopause: estriol and compounded hormones ↗
No FDA-approved drugs contain estriol. FDA does not establish estriol as a safer form of estrogen. General hormone-therapy guidance is not a product-specific facial risk estimate.
Dermatology guidance
American Academy of Dermatology — Caring for your skin in menopause ↗
Practical advice on dryness, sun protection, changing skin, and when an examination is needed.
Published study abstract
Schmidt et al. — Treatment of skin aging with topical estrogens (1996) ↗
Compared estriol and estradiol preparations in 59 women over six months. Historical formulations and limited follow-up do not establish current-brand equivalence or long-term safety.
Published study abstract
Schmidt et al. — Topical estrogens pilot study (1994) ↗
Small pilot: 8 estriol and 10 estradiol participants. Useful as early research, not a reliable probability of benefit.
Published study abstract
Kainz et al. — Systemic effects of facial estrogen ointment (1993) ↗
A small, short study cannot exclude uncommon or delayed effects, or establish no absorption for every formulation.